Posts Tagged ‘clinical trial’
Rob Kardashian Reuters
The 26-year-old has reportedly checked himself into rehab at The Meadows trauma and addiction treatment center in Arizona. According to reports, Kardashian has gained weight due to smoking marijuana, drinking alcohol and prescription cough syrup.
Read more on International Business Times
Smartphone App May Help People Overcome Alcoholism
WEDNESDAY, March 26, 2014 (HealthDay News) — A smartphone application, or "app," designed to tackle addiction has helped recovering alcoholics stay sober or reduce their risky drinking, a new clinical trial reports. Participants using the A-CHESS app …
Read more on WebMD
Question by xinx78: Does anyone know about Cancer Treatment Centers Of America?
I called and checked their website, they sound too good to be true, also they really don’t want to give out any free advice, esp when they can make money from a visit to their hospital. I found out it is a pvt hosptial and they don’t accept Government aid, funding or help, so that means they only accept the best of the best medical insurance and you need to be rich to even go there, intial deposit is $ 100,000 if you have no Medical coverage. So since this is purely based for the rich, not the poor, or working poor, are these treatment centers any good and are they worth all that money or what? Just curious if they can eradicate any type of oral cancer? If you went there or know of them, on a 10 star rating, what would you rate them as ? 10 being the best and 1 being poor.
Best answer:
Answer by Mary Boo
The medical is still treat like HMO. It should be something don about that. because cancer is cancer
Answer by quijibored
This is part of my answer to the other CTCA question asked by someone else this AM.
First off, there are no secret cancer treatments that are only available at CTCA so when looking for a cancer treatment facility you want the best hospital for your particular cancer that happens to be located near your home. Traveling long distances repeatedly when you are not feeling good gets old (and very expensive in out of pocket cash) real fast so you need to figure into the equation what degree of difficulty you will have making repeated trips to whatever facility you end up choosing.
Cancer Treatment Centers of America are private for profit hospitals that make certain you have the money to pay for their services. While they have modern facilities they are by no means able to offer all the cutting edge treatments available when compared to some of the other hospitals available for treating cancer like for instance MD Anderson in Houston. CTCA’s big advantage is their willingness to spend tons of money on advertising and not because the treatments available there are different than the treatments available at many other top rate cancer facilities.
The NCI has chosen about 35 cancer centers that they designate as comprehensive cancer centers meaning they are able to deal with complex cases of almost every type cancer. This also means that clinical trials are widely available – something that CTCA does not offer. Here is a link to find the nearest NCI designated comprehensive cancer center located nearest to you.
http://cancercenters.cancer.gov/cancer_c…
BTW- Do not get the self named “comprehensive cancer centers” mixed up with the NCI designated facilities. While they may still be very good hospitals, for whatever reason, the NCI has not yet designated them as an NCI facility.
B2B ID: Saralee Hofrichter, Saralee's Healing & Holistic Skin Care, Amherst
For the past 15 years, I worked at Kripalu Yoga Center as an esthetician. In addition, I helped open and worked at two esthetician rooms in Northampton. I have had my own private practice for 16 years. I hold a bachelor's degree with a concentration in …
Read more on GazetteNET
Parents of Texas 'affluenza' teen to pay part of state treatment
The state facility he has been sent to costs $ 715 a day. His parents had offered to pay for private treatment at a private out-of-state facility. The case set off an emotional debate after a psychologist for the teenager testified that his family's …
Read more on WHBL Sheboygan
Additional details released about plan for Hardin jail
A private corrections company in Louisiana has a tentative deal to turn a long-vacant Hardin jail into a treatment center that would draw federal Bureau of Indian Affairs inmates from across the region, company and local officials said Friday. Inmates …
Read more on Billings Gazette
Maryland Heights residents fight proposed rehab center
(KSDK) – The fight is on in Maryland Heights to keep a psychiatric and substance abuse treatment facility from opening. That center has a famous name attached to it. A healthcare company from Florida is partnering with former baseball star Darryl …
Read more on KSDK
Folsom man fights for clinical cancer drug trial to keep his wife alive
"We've kind of known there's no chance of her surviving," Mikaela's husband, Keith, said. Besides being by her side, Keith has spent the months since the diagnosis asking major drug companies to include Mikaela in clinical trials for new cancer treatments.
Read more on News10.net
Question by Kevin7: has the drug GRN-29 improved autism symptoms in mice?
science daily news
Best answer:
Answer by Hαяνεγ βoi 416™
*GRN-529
Agent Reduces Autism-Like Behaviors in Mice: Boosts Sociability, Quells Repetitiveness
ScienceDaily (Apr. 25, 2012) — National Institutes of Health researchers have reversed behaviors in mice resembling two of the three core symptoms of autism spectrum disorders (ASD). An experimental compound, called GRN-529, increased social interactions and lessened repetitive self-grooming behavior in a strain of mice that normally display such autism-like behaviors, the researchers say.
GRN-529 is a member of a class of agents that inhibit activity of a subtype of receptor protein on brain cells for the chemical messenger glutamate, which are being tested in patients with an autism-related syndrome. Although mouse brain findings often don’t translate to humans, the fact that these compounds are already in clinical trials for an overlapping condition strengthens the case for relevance, according to the researchers.
“Our findings suggest a strategy for developing a single treatment that could target multiple diagnostic symptoms,” explained Jacqueline Crawley, Ph.D., of the NIH’s National Institute of Mental Health (NIMH). “Many cases of autism are caused by mutations in genes that control an ongoing process — the formation and maturation of synapses, the connections between neurons. If defects in these connections are not hard-wired, the core symptoms of autism may be treatable with medications.”
Crawley, Jill Silverman, Ph.D., and colleagues at NIMH and Pfizer Worldwide Research and Development, Groton, CT, report on their discovery April 25th, 2012 in the journal Science Translational Medicine.
“These new results in mice support NIMH-funded research in humans to create treatments for the core symptoms of autism,” said NIMH director Thomas R. Insel, M.D. “While autism has been often considered only as a disability in need of rehabilitation, we can now address autism as a disorder responding to biomedical treatments.”
Crawley’s team followed-up on clues from earlier findings hinting that inhibitors of the receptor, called mGluR5, might reduce ASD symptoms. This class of agents — compounds similar to GRN-529, used in the mouse study — are in clinical trials for patients with the most common form of inherited intellectual and developmental disabilities, Fragile X syndrome, about one third of whom also meet criteria for ASDs.
To test their hunch, the researchers examined effects of GRN-529 in a naturally occurring inbred strain of mice that normally display autism-relevant behaviors. Like children with ASDs, these BTBR mice interact and communicate relatively less with each other and engage in repetitive behaviors — most typically, spending an inordinate amount of time grooming themselves.
Crawley’s team found that BTBR mice injected with GRN-529 showed reduced levels of repetitive self-grooming and spent more time around — and sniffing nose-to-nose with — a strange mouse.
Moreover, GRN-529 almost completely stopped repetitive jumping in another strain of mice.
“These inbred strains of mice are similar, behaviorally, to individuals with autism for whom the responsible genetic factors are unknown, which accounts for about three fourths of people with the disorders,” noted Crawley. “Given the high costs — monetary and emotional — to families, schools, and health care systems, we are hopeful that this line of studies may help meet the need for medications that treat core symptoms.”
http://www.sciencedaily.com/releases/2012/04/120425143634.htm
Negative Allosteric Modulation of the mGluR5 Receptor Reduces Repetitive Behaviors and Rescues Social Deficits in Mouse Models of Autism (Abstract)
http://stm.sciencemag.org/content/4/131/131ra51
Clinical trial testing new treatment for marijuana addiction
Behavioral Health Services of Pickens County is accepting marijuana smokers ages 18-50 for the trial funded by the National Institute on Drug Abuse (NIDA), according to Margaret K. Garrett, research liaison for the treatment center. “Generally we are …
Read more on Greenville News
Georgia Medical Cannabis Bill Amended, Heads to House Floor
The University of Mississippi, in 1986, contracted with the National Institute on Drug Abuse (NIDA) and the university's lab to grow, harvest, and process cannabis and to ship it to licensed facilities across the country for research. In the bill …
Read more on Atlanta Progressive News
Home + School Programs Modestly Slow Teen Prescription Drug Abuse
As a result, the U.S. Food and Drug Administration has recommended restricting access to painkillers such as Percocet, Oxycontin, and Vicodin. “These drugs are very available, and highly addictive,” said Max Crowley, Ph.D., an NIH Research Fellow at …
Read more on PsychCentral.com
Prevalence of high school seniors' marijuana use is expected to increase with …
The National Institute on Drug Abuse, Inter-university Consortium for Political and Social Research, and Monitoring the Future principal investigators, had no role in analysis, interpretation of results, or in the decision to submit the manuscript for …
Read more on EurekAlert (press release)